Ask AI
Back Back
ProCE Banner Activity

CE

Case Challenge: Improving Treatment Adherence and Persistence to CDK4/6 Inhibitor Treatment of HR+/HER2- EBC

Case Challenge

CDK4/6 inhibitors are essential to the optimal adjuvant treatment of high-risk HR-positive/HER2-negative early breast cancer. However, clinical questions remain regarding patient eligibility and optimal therapy selection, particularly for those with comorbid conditions and complex medication regimens. In this activity, you will walk through a patient case and make clinical decisions to optimize care for a patient with  high-risk HR-positive/HER2-negative early breast cancer. Topics include eligibility criteria for adjuvant CDK4/6 inhibitors, strategies for counseling patients about treatment safety, making management decisions based on comorbidities, potential drug interactions, treatment goals, and emerging adverse events.

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 21, 2026

Expiration: January 20, 2027

Begin Activity

Share

Faculty

Heather Moore

Heather Moore, PharmD, BCOP, CPP

Clinical Oncology Pharmacist, Breast Oncology
Duke University Hospital, Duke Cancer Institute
Durham, North Carolina

Provided by

Provided by National Comprehensive Cancer Network in collaboration with Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from Lilly and Novartis.

Lilly

Novartis

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals involved in the care of patients with HR-positive/HER2-negative early breast cancer.

Program Learning Goal

This activity aims to improve learners’ knowledge and competence at integrating CDK4/6 inhibitors into practice to improve clinical outcomes in patients with HR-positive/HER2-negative early breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Support open and frequent patient-clinician communication to enable effective counseling on the benefits vs potential risks of adjuvant CDK4/6 inhibitor treatment, reporting of patient-felt toxicities, and screening for barriers to adherence/persistence

  • Implement proactive toxicity monitoring, dose modification, and supportive care to enable patient adherence and persistence to CDK4/6 inhibitor treatment for HR-positive/HER2-negative EBC

Financial Disclosures

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers, ​and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.​

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions 
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients. ​

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.​

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.​

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Primary Author

Heather Moore, PharmD, BCOP, CPP: consultant/advisor/speaker: AstraZeneca, Genentech, Gilead, Lilly, Novartis.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 21, 2026, through January 20, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Continuing Pharmacy Education

NCCN designates this knowledge-based continuing education activity for 0.5 contact hours (0.05 CEUs) of continuing education credit. UAN: JA4008196-0000-26-069-H01-P 

Type of Activity: Knowledge​

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.